Open Innovation a Must in New Drug Development
The Korea Biomedical Review reported that the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and the Korea Research-based Pharma Industry Association recently held a meeting of the government, pharmaceutical representatives, and experts. “As research and development activities for new drugs are becoming open innovation-based ones, innovative ideas, knowledge, and know-how are being shared without boundaries,” said Lee Jung-hee, board chair of the KPBMA. “Korea will be able to become a pharmaceutical powerhouse if the aggressive efforts of the pharma industry are combined with bold open innovation and the government’s practical support.”
Click here to read the full article.